Off-Target Effects Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his philosophy on running an investment firm
Jun 25
1 min read
He describes to Matt how the market has become more efficient since he started in the 1990's. He shares his perspective on single-asset vs pipeline companies, and today's M&A dynamic. Plus, his goal of being unbiased as an investor and how he tries to create an environment at Perceptive where that style is instilled in his analysts.
.png){kind=logo}